CORDIS
EU research results

CORDIS

English EN
Personalized Tissue-Engineered Veins as the first Cure for Patients with Chronic Venous Insufficiency

Personalized Tissue-Engineered Veins as the first Cure for Patients with Chronic Venous Insufficiency

Objective

This project will commercialize P-TEV - a unique personalized tissue engineered vein for the treatment of patients with severe Chronic Venous Insufficiency (CVI).
CVI is a progressive medical condition in which the valves of the deep veins of the leg are not functioning properly. The most severe stage is CVI with leg ulceration. No effective treatment is available, and a large number of patients would directly benefit from venous vascular surgery. These patients cannot be cured today because no suitable grafts for replacement of the dysfunctional venous valves have yet been developed. There are no synthetic products which could replace the function of the bicuspid valves found in the leg veins and the risks associated with allotransplantation are too high.
VERIGRAFT’s technology is the first one positioned to break this paradigm and fill the existing market gap. The technology allows the personalization of blood vessels by de- and recellularization. In short, a donated tissue is decellularized, removing all immunogenic donor cells and DNA. This results in a clean extracellular matrix scaffold with intact 3D structural properties. Subsequently, this scaffold is seeded with the patient´s own cells, derived from a small sample of peripheral blood.
This unique technology turns an allogeneic (“foreign”) tissue into an autologous (“personalized”) one and thus avoids transplant rejection without the need for immunosuppression.
The clinical proof-of-concept for P-TEV is established. The project will include the clinical study and GMP process development that will grant VERIGRAFT market access by 2019 and serve as a steppingstone to marketing approval by the European Medicines Agency.
The EU-added value of the project is unparalleled, as it constitutes a breakthrough in one of future medicine's most promising fields – advanced personalized regenerative medicine, bringing significant long-term budgetary relief to healthcare systems.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

VERIGRAFT AB

Address

Arvid Wallgrens Backe 20
413 46 Goteborg

Sweden

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

EU Contribution

€ 2 184 603,75

Project information

Grant agreement ID: 778620

Status

Grant agreement terminated

  • Start date

    1 September 2017

  • End date

    31 August 2019

Funded under:

H2020-EU.3.1.3.

  • Overall budget:

    € 2 184 603,75

  • EU contribution

    € 2 184 603,75

Coordinated by:

VERIGRAFT AB

Sweden